Similar Items: Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
- Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
- Sex differences in neural stress responses over psychosocial stress exposure
- Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan
- Perampanel as add‐on in high‐grade glioma–related epilepsy: Seizure control and QoL in a prospective, multicenter, real‐world 6‐month follow‐up study
- Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China
- Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE